TrialAnnals of the rheumatic diseases2009

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial.

M Schiff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.